-transparent.png){kind=logo}
We have treated 40 patients with thymoma. All the 18 with benign thymoma were treated with resection alone and none had a tumor recurrence or died from disease-related causes. Postoperative survival in this group ranged from 2 months to 14 years. Of the 22 patients with malignant thymoma, 2 underwent total resection, 10 partial resection and 10 were non-resectable. Fifteen of the 20 patients with non-resectable and partially excised thymomas were given radiotherapy. The cumulative 5- and 10-year survival rate of irradiation treated patients was 45.6%, and 34.4%, respectively. Of 6 non-irradiated patients, only one who underwent complete excision of tumors survived for more than 10 years, and 5 died within 3 years after treatment. Based on our findings we suggest that all patients with malignant thymoma, irrespective of the extent of surgical treatment, should be given postoperative irradiation.
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
January 2001,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
August 1974,
Cancer,
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
February 1985,
The Annals of thoracic surgery,
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
May 2017,
Zhonghua bing li xue za zhi = Chinese journal of pathology,
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
September 2015,
Zhonghua bing li xue za zhi = Chinese journal of pathology,
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
February 2018,
Clinical advances in hematology & oncology : H&O,
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
January 1997,
The Journal of thoracic and cardiovascular surgery,
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
December 2007,
Orthopedics,
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
January 2020,
International journal of clinical and experimental pathology,
N Hara, and
T Yoshida, and
T Furukawa, and
K Inokuchi
July 1992,
Cancer,
